---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-152864"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:38:19.397781+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Evommune hosts webcast on MRGPRX2 inhibition for migraine treatment

## Summary
- Presentation reviews migraine treatment landscape and potential role of MRGPRX2 inhibition.
- No new clinical data, financial results, or regulatory milestones disclosed.
- Webcast replay available on company IR website.

## SEC filing metadata
- accession: 0001193125-26-152864
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526152864/0001193125-26-152864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526152864/evmn-20260413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-152864
- JSON: https://secwatch.observer/filing/0001193125-26-152864.json
- Plain text: https://secwatch.observer/filing/0001193125-26-152864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.